Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Acetylcarnitine: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 19:57, 16 February 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 477036906 of page Acetylcarnitine for the Chem/Drugbox validation project (updated: 'ChEMBL').  Latest revision as of 01:34, 2 December 2024 edit Citation bot (talk | contribs)Bots5,391,717 edits Added issue. | Use this bot. Report bugs. | #UCB_CommandLine 
Line 1: Line 1:
{{Short description|Form of L-carnitine}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457802004 | verifiedrevid = 477240228
| IUPAC_name = (''R'')-3-acetyloxy-4-trimethylammonio-butanoate | IUPAC_name = (''R'')-3-Acetyloxy-4-trimethylammonio-butanoate
| image = (R)-Acetylcarnitine V.3.svg | image = Acetylcarnitine.svg
| width = 210 | width = 200


<!--Clinical data--> <!--Clinical data-->
| tradename = | tradename =
| Drugs.com = {{drugs.com|international|acetylcarnitine}} | Drugs.com = {{drugs.com|international|acetylcarnitine}}
| pregnancy_category = | pregnancy_category =
| legal_status = | legal_status = OTC
| routes_of_administration = | routes_of_administration = Oral


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability = >10%
| metabolism = | metabolism =
| elimination_half-life = 28.9 - 35.9 hours<ref>{{cite journal | vauthors = Cao Y, Wang YX, Liu CJ, Wang LX, Han ZW, Wang CB | title = Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers | journal = Clinical and Investigative Medicine | volume = 32 | issue = 1 | pages = E13–E19 | date = February 2009 | pmid = 19178874 | doi = 10.25011/cim.v32i1.5082 | doi-access = free }}</ref>
| excretion = | excretion =


<!--Identifiers--> <!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3040-38-8 | CAS_number = 3040-38-8
| ATC_prefix = N06 | ATC_prefix = N06
| ATC_suffix = BX12 | ATC_suffix = BX12
| PubChem = 7045767 | PubChem = 1
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08842
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5406074 | ChemSpiderID = 5406074
Line 33: Line 35:
| ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 57589 | ChEBI = 57589
| ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 1358846 --> | ChEMBL = 1697733

⚫ | C=9 | H=17 | N=1 | O=4
<!--Chemical data-->
| molecular_weight = 203.236
⚫ | C = 9 | H = 17 | N = 1 | O = 4
| smiles = C(=O)C(OC(=O)C)C(C)(C)C | smiles = C(=O)C(OC(=O)C)C(C)(C)C
| InChI = 1/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1
| InChIKey = RDHQFKQIGNGIED-MRVPVSSYBU
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1 | StdInChI = 1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RDHQFKQIGNGIED-MRVPVSSYSA-N | StdInChIKey = RDHQFKQIGNGIED-MRVPVSSYSA-N
|drug_name=|alt=|caption=|type=|MedlinePlus=|licence_EU=|pregnancy_AU=|pregnancy_US=|licence_US=}}
}}

'''Acetyl-<small>L</small>-carnitine''', '''ALCAR''' or '''ALC''', is an ] form of <small>L</small>-]. It is naturally produced by the human body, and it is available as a dietary supplement. Acetylcarnitine is broken down in the blood by ] ]s to carnitine which is used by the body to transport fatty acids into the ] for breakdown and energy production.

== Biochemical production and action ==
] is both a ] and made by the body as needed; it serves as a substrate for important reactions in which it accepts and gives up an ]. Acetylcarnitine is the most abundant naturally occurring derivative and is formed in the reaction:

:] + carnitine {{eqm}} ] + acetylcarnitine

where the acetyl group displaces the hydrogen atom in the central hydroxyl group of carnitine.<ref name=1988Bieber>{{cite journal | vauthors = Bieber LL | title = Carnitine | journal = Annual Review of Biochemistry | volume = 57 | pages = 261–283 | year = 1988 | issue = 1 | pmid = 3052273 | doi = 10.1146/annurev.bi.57.070188.001401 }}</ref><ref name="Stephens2007">{{cite journal | vauthors = Stephens FB, Constantin-Teodosiu D, Greenhaff PL | title = New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle | journal = The Journal of Physiology | volume = 581 | issue = Pt 2 | pages = 431–444 | date = June 2007 | pmid = 17331998 | pmc = 2075186 | doi = 10.1113/jphysiol.2006.125799 }}</ref> Coenzyme A (CoA) plays a key role in the ] in ], which is essential for the production of ], which powers many reactions in cells; acetyl-CoA is the primary substrate for the Krebs cycle, once it is de-acetylated, it must be re-charged with an acetyl-group in order for the Krebs cycle to keep working.<ref name=Stephens2007/>

Most cell types appear to have transporters to import carnitine and export acyl-carnitines, which seems to be a mechanism to dispose of longer-chain moieties; however many cell types can also import ALCAR.<ref name=1988Bieber/>

Within cells, carnitine plays a key role in importing acyl-CoA into mitochondria; the acyl-group of the acyl-CoA is transferred to carnitine, and the acyl-carnitine is imported through both mitochondrial membranes before being transferred to a CoA molecule, which is then ] to acetyl-CoA. A separate set of enzymes and transporters also plays a buffering role by eliminating acetyl-CoA from inside mitochondria created by the ] that is in excess of its utilization by the Krebs cycle; carnitine accepts the acetyl moiety and becomes ALCAR, which is then transported out of the mitochondria and into the cytosol, leaving free CoA inside the mitochondria ready to accept new import of fatty acid chains.<ref name=Stephens2007/> ALCAR in the cytosol can also form a pool of acetyl-groups for CoA, should the cell need it.<ref name=Stephens2007/>

Excess acetyl-CoA causes more carbohydrates to be used for energy at the expense of fatty acids. This occurs by different mechanisms inside and outside the mitochondria. ALCAR transport decreases acetyl-CoA inside the mitochondria, but increases it outside.<ref>{{cite journal | vauthors = Kiens B | title = Skeletal muscle lipid metabolism in exercise and insulin resistance | journal = Physiological Reviews | volume = 86 | issue = 1 | pages = 205–243 | date = January 2006 | pmid = 16371598 | doi = 10.1152/physrev.00023.2004 }}</ref><ref>{{cite journal | vauthors = Lopaschuk GD, Gamble J | title = The 1993 Merck Frosst Award. Acetyl-CoA carboxylase: an important regulator of fatty acid oxidation in the heart | journal = Canadian Journal of Physiology and Pharmacology | volume = 72 | issue = 10 | pages = 1101–1109 | date = October 1994 | pmid = 7882173 | doi = 10.1139/y94-156 }}</ref>

== Health effects ==
Carnitine and ALCAR supplements carry warnings of a risk that they promote seizures in people with epilepsy, but a 2016 review found this risk to be based only on animal trials.<ref>{{cite journal | vauthors = Zeiler FA, Sader N, Gillman LM, West M | title = Levocarnitine induced seizures in patients on valproic acid: A negative systematic review | journal = Seizure | volume = 36 | pages = 36–39 | date = March 2016 | pmid = 26889779 | doi = 10.1016/j.seizure.2016.01.020 | doi-access = free }}</ref>

== Research ==

=== Reviews ===
* ]: Meta-analyses from 2015 and 2017 both conclude that the current evidence suggests ALC reduces pain from peripheral neuropathy with few adverse effects.<ref>{{cite journal | vauthors = Li S, Li Q, Li Y, Li L, Tian H, Sun X | title = Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials | journal = PLOS ONE | volume = 10 | issue = 3 | pages = e0119479 | date = 2015-01-01 | pmid = 25751285 | pmc = 4353712 | doi = 10.1371/journal.pone.0119479 | doi-access = free | bibcode = 2015PLoSO..1019479L }}</ref> The 2017 review also suggested ALC improved ] parameters.<ref>{{Cite journal| vauthors = Veronese N |year=2017|title=Effect of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis|journal=European Geriatric Medicine|volume=8|issue=2|pages=117–122|doi=10.1016/j.eurger.2017.01.002|hdl=10138/235591|s2cid=56342481 |hdl-access=free}}</ref> Both called for more randomized controlled trials. An updated Cochrane review in 2019 of four studies with 907 participants was very uncertain as to if ALC caused a pain reduction after 6 to 12 months of treatment.<ref>{{cite journal | vauthors = Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA | title = Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy | journal = The Cochrane Database of Systematic Reviews | volume = 2019 | issue = 6 | pages = CD011265 | date = June 2019 | pmid = 31201734 | pmc = 6953387 | doi = 10.1002/14651858.CD011265.pub2 }}</ref>
* ] (CIPN): A review of two studies concluded that ALC may be a treatment option for ]- and ]-induced CIPN, while a clinical trial showed it did not prevent CIPN and appeared to worsen the conditions in ] therapy.<ref>{{cite journal | vauthors = Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L | title = Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review | journal = Clinical Nutrition | volume = 32 | issue = 6 | pages = 888–893 | date = December 2013 | pmid = 23647723 | doi = 10.1016/j.clnu.2013.04.007 }}</ref><ref>{{cite journal | vauthors = Brami C, Bao T, Deng G | title = Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review | journal = Critical Reviews in Oncology/Hematology | volume = 98 | pages = 325–334 | date = February 2016 | pmid = 26652982 | pmc = 4727999 | doi = 10.1016/j.critrevonc.2015.11.014 }}</ref>
* Male infertility: Scientific reviews from 2016 and 2014 showed mixed results, with some studies showing a positive relationship between ALC and sperm motility, and others showing no relationship.<ref>{{cite journal | vauthors = Ahmadi S, Bashiri R, Ghadiri-Anari A, Nadjarzadeh A | title = Antioxidant supplements and semen parameters: An evidence based review | journal = International Journal of Reproductive Biomedicine | volume = 14 | issue = 12 | pages = 729–736 | date = December 2016 | pmid = 28066832 | pmc = 5203687 | doi = 10.29252/ijrm.14.12.729 | doi-broken-date = 1 November 2024 }}</ref><ref>{{cite journal | vauthors = Arcaniolo D, Favilla V, Tiscione D, Pisano F, Bozzini G, Creta M, Gentile G, Menchini Fabris F, Pavan N, Veneziano IA, Cai T | display-authors = 6 | title = Is there a place for nutritional supplements in the treatment of idiopathic male infertility? | journal = Archivio Italiano di Urologia, Andrologia | volume = 86 | issue = 3 | pages = 164–170 | date = September 2014 | pmid = 25308577 | doi = 10.4081/aiua.2014.3.164 | doi-access = free }}</ref>
* Dementia: A 2003 ] review sought to determine the safety and efficacy of ALCAR in dementia but the reviewers found only clinical trials studies on Alzheimer's disease; the review found that the pharmacology of ALCAR was poorly understood and that based on the lack of efficacy, ALCAR was unlikely to be an important treatment for AD.<ref>{{cite journal | vauthors = Hudson S, Tabet N | title = Acetyl-L-carnitine for dementia | journal = The Cochrane Database of Systematic Reviews | volume = 2003 | issue = 2 | pages = CD003158 | year = 2003 | pmid = 12804452 | pmc = 6991156 | doi = 10.1002/14651858.CD003158 | type = Systematic review }}</ref>
* Depression: One 2014 review assessed the use of ALCAR in fourteen clinical trials for various conditions with depressive symptoms; the trials were small (ranging from 20 to 193 subjects) and their design was so different that results could not be generalized; most studies showed positive results and a lack of adverse effects. The mechanism of action by which ALCAR could treat depression is not known.<ref>{{cite journal | vauthors = Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU | title = A review of current evidence for acetyl-l-carnitine in the treatment of depression | journal = Journal of Psychiatric Research | volume = 53 | pages = 30–37 | date = June 2014 | pmid = 24607292 | doi = 10.1016/j.jpsychires.2014.02.005 }}</ref> A meta-analysis from 2014 concluded that ALCAR could only be recommended for the treatment of persistent depressive disorder if ] was deemed improbable.<ref>{{cite journal | vauthors = Kriston L, von Wolff A, Westphal A, Hölzel LP, Härter M | title = Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis | journal = Depression and Anxiety | volume = 31 | issue = 8 | pages = 621–630 | date = August 2014 | pmid = 24448972 | doi = 10.1002/da.22236 | s2cid = 41163109 | doi-access = free }}</ref> A 2018 systematic review and meta-analysis of 12 randomized controlled trials found "supplementation significantly decreases depressive symptoms compared with placebo/no intervention, while offering a comparable effect with that of established antidepressant agents with fewer adverse effects." The review also indicates that "the effect of ALC in younger subjects was not more effective than placebo in improving these symptoms." indicating a need for more research explaining the age/effect relation.<ref>{{cite journal | vauthors = Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S | title = Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis | journal = Psychosomatic Medicine | volume = 80 | issue = 2 | pages = 154–159 | date = Feb–Mar 2018 | pmid = 29076953 | doi = 10.1097/PSY.0000000000000537 | s2cid = 7649619 }}</ref>
* ]: A 2015 Cochrane review of ALCAR in fragile X syndrome found only two placebo-controlled trials, each of low quality, and concluded that ALCAR is unlikely to improve intellectual functioning or hyperactive behavior in children with this condition.<ref>{{cite journal | vauthors = Rueda JR, Guillén V, Ballesteros J, Tejada MI, Solà I | title = L-acetylcarnitine for treating fragile X syndrome | journal = The Cochrane Database of Systematic Reviews | volume = 19 | issue = 5 | pages = CD010012 | date = May 2015 | pmid = 25985235 | doi = 10.1002/14651858.CD010012.pub2 | pmc = 10849109 }}</ref>
* ]: ALCAR has been studied in hepatic encephalopathy, a complication of ] involving neuropsychiatric impairment; ALCAR improves blood ammonia levels and generates a modest improvement in psychometric scores but does not resolve the condition – it may play a minor role in managing the condition.<ref>{{cite journal | vauthors = Jawaro T, Yang A, Dixit D, Bridgeman MB | title = Management of Hepatic Encephalopathy: A Primer | journal = The Annals of Pharmacotherapy | volume = 50 | issue = 7 | pages = 569–577 | date = July 2016 | pmid = 27126547 | pmc = 1503997 | doi = 10.1177/1060028016645826 | s2cid = 32765158 }}</ref><nowiki/>

=== Studies ===
* In a small clinical study, when ALCAR was administered intravenously and insulin levels were held steady and a meal low in carnitine but high in carbohydrates was taken by healthy young men, ALCAR appeared to decrease glucose consumption in favor of fat oxidation.<ref name="Stephens2007" />
* ] decay and ] to RNA/DNA increases with age in the rat ], a region of the brain associated with ].<ref name = Liu2002>{{cite journal | vauthors = Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN | display-authors = 6 | title = Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-<small>L</small>-carnitine and/or ''R'' -α-lipoic acid | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 99 | issue = 4 | pages = 2356–2361 | date = February 2002 | pmid = 11854529 | pmc = 122369 | doi = 10.1073/pnas.261709299 | doi-access = free }}</ref> Memory performance declines with age. These increases in decay and damage, and memory loss itself, can be partially reversed in old rats by feeding acetyl-L-carnitine.<ref name = Liu2002/>

== References ==
{{Reflist|2}}

== Further reading ==
* {{Pauling|id=othernuts/carnitine|title=L-Carnitine|author =Jane Higdon}}
* , ''University of Maryland Medical Center''

{{Dietary supplements}}
{{Antioxidants}}

{{Cholinergics}}

]
]
]
]
]
]
]